摘要
目的:探讨a-L-岩藻糖苷酶(a-L-Fucosidase,AFU)对诊断原发性肝癌(primaryhepaticcarcinoma,PHC)的临床意义。方法:对80例正常人、33例肝癌患者、37例肝炎患者、42例肝硬化患者、10例转移性肝癌患者和37例其它恶性肿瘤患者所测的血清检测AFU活性值并进行统计后,比较各组AFU水平差异。结果:血清AFU水平,PHC组(41.2±14.1U/L)明显高于正常对照组(20.5±7.2U/L)、转移性肝癌组(22.2±13.6U/L)、其它恶性肿瘤组(22.0±7.1U/L),P<0.01和肝硬化组(25.5±13.0U/L)(0.01<P<0.05)。结论:a-L-岩藻糖苷酶是PHC的特异性标志物,可用于PHC的早期诊断。
Objective： To analyse the clinical significance of a-L-Fucosidase （AFU） in the diagnosis of primary hepatic carcinoma （PHC）.Methods： The activity of serum AFU was measured in 33 patients with PHC, 42 patients with cirrhosis, 37 patients whit hepatitis, 10 patients with secondary liver cancer, 37 patients with other malignant tumors and 80 normal persons. The differences of the level of AFU between the groups were compared. Results： The mean serum AFU activity was significantly higher in patients with PHC （41.2 ±14.1 U/L）than that in normal persons （20.5± 7.2U/L）, secondary liver cancer （22.2 ± 13.6 U/L）, other kinds of malignant tumors （22.0 ± 7.1 U/L）,P〈O.O1 and hepatocirrhosis （25.5 ± 13.0 U/L）, 0.01〈P〈0.05. Conclusion：AFU is a specific maker in the PHC and can be used to diagnosis early PHC.
出处
《重庆医科大学学报》
CAS
CSCD
2006年第3期440-442,共3页
Journal of Chongqing Medical University
